New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment
about
High incidence of somatic BAP1 alterations in sporadic malignant mesotheliomaNew insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomasConsensus report of the 2015 Weinman International Conference on MesotheliomaGender-Specific Molecular and Clinical Features Underlie Malignant Pleural MesotheliomaLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesSwitching off malignant mesothelioma: exploiting the hypoxic microenvironmentBAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.A new standard for malignant pleural mesotheliomaBiology of advanced uveal melanoma and next steps for clinical therapeutics.Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.BAP1 missense mutation c.2054 A>T (p.E685V) completely disrupts normal splicing through creation of a novel 5' splice site in a human mesothelioma cell line.MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.PBRM1 and BAP1 as novel targets for renal cell carcinomaThe Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment.Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens.Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cellsTumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome.
P2860
Q24170431-0245101B-4F6E-46C5-925B-54871FE304A1Q26859274-2668FD72-038B-4794-A00C-F32BA29FA5EBQ27908468-4AE24D93-C3A2-4247-9610-102B1D17B6D7Q28384371-637A2E5F-9A97-4650-BE97-DB74F10A874BQ28395597-6378AC66-E9DD-4542-B499-2A66BF00B65CQ29248727-6E96727C-D7B6-4DD9-AD5D-2E9F6BD56A40Q30412528-4AA8B498-74BA-46C6-819D-E694F589EE54Q33778076-06DE0A3A-C429-4A28-9BB7-71008BDD8EBCQ35079709-577A50A8-C607-4137-B6C5-11A45EE7CE62Q35129478-9C3DEC68-BFDA-4F73-A6CC-7D2F8D91EEDAQ35591969-982BA69F-AF1F-42A4-8D99-F9CFC942079BQ37049227-5F119BA5-BBF8-43A9-9935-E28B315611C1Q38122565-6DD3F6A8-416D-45DA-B402-5EAED056F36EQ38214084-C212C135-F040-4D8C-A89C-066A5A353D23Q38459546-CFF05AE8-1D8F-4F82-9409-879BC41C51F7Q38646960-C5FF2EEB-6627-4641-B18E-C89DB50E98B6Q38794945-3D2E6A48-4C42-4B16-84F6-597F5BE10C09Q38870857-AF169637-70AC-4EE7-B02F-C5B0D778F5E1Q42006082-C4F8FDA4-C49C-4780-80BE-8A07178FEA79Q47624664-52E82361-E35B-4466-A132-03FF695224B3Q47672873-80B5077A-F629-44DE-B212-61E090981831Q49996923-839C305D-FDE3-42AC-B15D-F3DF49017B1FQ53316010-AF680A68-28FE-4504-A0AF-1583CBAA663BQ53533612-FBE368C1-3F47-42F3-9C53-4D67C725C7AB
P2860
New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
New strategies in pleural meso ...... evelopment and risk assessment
@ast
New strategies in pleural meso ...... evelopment and risk assessment
@en
type
label
New strategies in pleural meso ...... evelopment and risk assessment
@ast
New strategies in pleural meso ...... evelopment and risk assessment
@en
prefLabel
New strategies in pleural meso ...... evelopment and risk assessment
@ast
New strategies in pleural meso ...... evelopment and risk assessment
@en
P2093
P2860
P1476
New strategies in pleural meso ...... evelopment and risk assessment
@en
P2093
Filippo Giancotti
Lee M Krug
Marjorie G Zauderer
Matthew Bott
Robert McMillan
Tatsuo Ito
P2860
P304
P356
10.1158/1078-0432.CCR-11-2375
P407
P50
P577
2012-07-23T00:00:00Z